A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

This study is testing whether a combination of two drugs — saruparib (AZD5305, a PARP inhibitor that targets DNA repair) and darolutamide (a hormone-blocking drug) — can shrink prostate cancer tumors before surgery, and studying how the drugs affect the tumor biology. **You may be eligible if...** - You are male and at least 18 years old - You have localized prostate cancer that is classified as unfavourable intermediate, high, or very high risk - You are considered a good candidate for prostate removal surgery (radical prostatectomy) - Your organs are functioning well enough for treatment **You may NOT be eligible if...** - You have already received treatment for prostate cancer - You have metastatic (spread) prostate cancer - You have significant other health conditions that would make the surgery or treatment unsafe - You are taking medications that interact with the study drugs Talk to your doctor to see if this trial is right for you.